Citi raised the firm’s price target on Beam Therapeutics (BEAM) to $64 from $56 and keeps a Buy rating on the shares. With positive BEAM-302 ...
Beam Therapeutics said it used a form of CRISPR called base editing to correct, in several patients, a mutation that drives a ...
As previously reported, Scotiabank upgraded Beam Therapeutics (BEAM) to Outperform from Sector Perform with a price target of $40, up from $25, ...
Retired NFL star Rob Gronkowski appeared on Ford CEO Jim Farley's podcast, "Drive," to discuss cars and careers. The podcast, available on platforms like YouTube and Spotify, features Farley ...
Dealbreaker on MSN2d
Beam Base Editor’s Early Data in Rare Liver Disease Tee Up $500M Stock Sale in Tough MarketA Beam Therapeutics gene-editing therapy designed to fix a mutation at the root of a rare liver protein deficiency now has ...
After hours: March 12 at 7:46:03 PM EDT ...
After hours: March 10 at 7:54:03 PM EDT Loading Chart for BEEM ...
© 2025 The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback